Mink Therapeutics, Inc. (INKT) Live Share Price, Invest From India

Mink Therapeutics, Inc. Stock Performance

as on March 28, 2026 at 6:59 am IST

Day's Low
Day's High
$9.76
Day's Price Range
$11.94
$11.08
11.91%
Downside
7.76%
Upside
52 Week's Low
52 Week's High
$6.34
52-Week Price Range
$76.00
$11.08
42.78%
Downside
585.92%
Upside

Mink Therapeutics, Inc. share price movements today

Previous Close: $9.63
Open: $9.76
Volume: 375.4K
Day's Low - High: $9.76 - $11.94
52 Week Low - High: $6.34 - $76.00

Mink Therapeutics, Inc. Historical Returns

1 Month Return: + 0.64 %
3 Month Return: -7.78 %
1 Year Return: + 22.04 %
3 Year Return: -47.77 %
5 Year Return: 0 %

Mink Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Mink Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$45.2M

EPS (TTM)

-3.07

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-12.2M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-1238.98%

Mink Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Mink Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Mink Therapeutics, Inc.	BUY	$45.2M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$43.5B	132.92%	140.84	8.45%
Vertex Pharmaceuticals Incorporated	BUY	$115.2B	101.77%	29.58	32.94%
Beone Medicines Ltd	NA	$31.8B	NA	112.58	5.37%
Regeneron Pharmaceuticals, Inc.	BUY	$80.0B	54.69%	18.25	31.41%

Stock Returns calculator for Mink Therapeutics, Inc. Stock including INR - Dollar returns

The Mink Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Mink Therapeutics, Inc. investment value today

Current value as on today

₹1,33,211

Returns

₹33,211

(+33.21%)

Returns from Mink Therapeutics, Inc. Stock

₹22,702 (+22.7%)

Dollar Returns*

₹10,509 (+10.51%)

Analyst Recommendation on Mink Therapeutics, Inc. Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Mink Therapeutics, Inc.. Average target price of $39

Mink Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Mink Therapeutics, Inc..

What analysts predicted

71.59%UPSIDE

Target Price

$39

Current Price

$11.08

Analyzed by

10 Analysts

Target

$39.00

Mink Therapeutics, Inc. target price $39, a slight upside of 71.59% compared to current price of $11.08. According to 10 analysts rating.

Mink Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Mink Therapeutics, Inc. Stock has increased by 311% in the last 30 days, reflecting an upward trend in search activity.

Time period: February 26, 2026 to March 28, 2026

Change:311% versus previous 30 day period

Mink Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	-	-	-11,708	-	-	-	3,769	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-6	-5	-5	-3	-2	-1	-2	-2	-3	-2
EBITDA	-6	-5	-5	-3	-2	-1	-2	-2	-4	-2
Interest Expense	-	-	168	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-6	-5	-5	-3	-2	-1	-2	-2	-4	-2
Income Tax Expense	6,489	0	0	0	-	-	-	-	-	-
Net Income	-6	-5	-5	-3	-2	-1	-2	-2	-4	-2
Net Profit Margin	0.00%	0.00%	0.05%	0.00%	0.00%	0.00%	-0.07%	0.00%	0.00%	0.00%

Mink Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	0	-	-	2,704	-	-
Gross Profit	0	0	0	0	0	0
Operating Income	-22	-10	-18	-30	-22	-10
EBITDA	-22	-13	-27	-27	-22	-10
Interest Expense	1	2	2	0	-	-
Depreciation	0	0	0	0	0	0
Income Before Tax	-23	-16	-30	-27	-22	-10
Income Tax Expense	2	0	-7	-3	0	-10,774
Net Income	-23	-16	-30	-27	-22	-10
Net Profit Margin	-3451.46%	0.00%	0.00%	-1.03%	0.00%	0.00%

Mink Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	-5	-5	-3	-2	-1	-2	-2	-4	-2
Operating Cash Flow	-4	-3	-2	-2	-2	-1	-1,340	-1	0
Investing Cash Flow	0	-73	-	-	-	-	-	-	-
Financing Cash Flow	0	0	5	5	0	0	0	0	13
Change in Cash	-4	-3	2	3	-2	-1	-1,342	-1	12

Mink Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-16	-30	-27	-22	-10
Operating Cash Flow	-8	-12	-18	-15	-9
Investing Cash Flow	0	0	0	0	-
Financing Cash Flow	11	49	0	0	10
Change in Cash	2	36	-19	-16	1

Global Institutional Holdings in Mink Therapeutics, Inc.

Funds	Holdings
Longbow Finance SA	0.36%
Longbow Finance SA	0.36%
Northwestern Mutual Wealth Management Co	0%
Northwestern Mutual Wealth Management Co	0%
Advisor Group Holdings, Inc.	0%

See all

Insights on Mink Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, INKT has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, -11.70B → 3.76B (in $), with an average increase of 410.6% per quarter
POSITIVE IMPACT
Price Rise
In the last 7 days, INKT stock has moved up by 17.1%
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -4.23M → -2.88M (in $), with an average increase of 46.8% per quarter
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 68.3% return, outperforming this stock by 116.1%

About Mink Therapeutics, Inc.

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Organisation	Mink Therapeutics, Inc.
Headquarters	149 Fifth Avenue, New York, NY, United States, 10010
Industry	Services
CEO	Dr. Garo H. Armen Ph.D.
E-voting on shares	Click here to vote

Key Management of Mink Therapeutics, Inc.

Name	Title
Dr. Garo H. Armen Ph.D.	Executive Chairman

FAQs

What is Mink Therapeutics, Inc. share price today?

Mink Therapeutics, Inc. share price today is $11.08 as on March 28, 2026 at 1:29 am IST at the close of the market. Mink Therapeutics, Inc. share today touched a day high of $11.94 and a low of $9.76.

What is the 52 week high and 52 week low for Mink Therapeutics, Inc. share?

Mink Therapeutics, Inc. share touched a 52 week high of $76 on July 11, 2025 and a 52 week low of $6.34 on May 12, 2025. Mink Therapeutics, Inc. stock price today i.e. March 28, 2026 at 1:29 am IST is closed at $11.08,which is 85.42% down from its 52 week high and 74.76% up from its 52 week low.

What is Mink Therapeutics, Inc.'s market capitalisation today?

Mink Therapeutics, Inc. market capitalisation is $0.00T as on March 28, 2026 at 1:29 am IST.

How to invest in Mink Therapeutics, Inc. Stock (INKT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Mink Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Mink Therapeutics, Inc. Shares that will get you 0.1354 shares as per Mink Therapeutics, Inc. share price of $11.08 per share as on March 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Mink Therapeutics, Inc. Stock (INKT) from India?

Indian investors can start investing in Mink Therapeutics, Inc. (INKT) shares with as little as ₹94.651 or $1 (as of March 28, 2026 at 2:39 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹946.51 in Mink Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on March 28, 2026 at 2:39 pm IST). Based on Mink Therapeutics, Inc. share’s latest price of $11.08 as on March 28, 2026 at 1:29 am IST, you will get 0.9025 shares of Mink Therapeutics, Inc.. Learn more about fractional shares .